SCHEMBL206014

SCHEMBL206014

CN(C)C1(Cc2cccc(Cl)c2)CCC(NC(=O)CCC(=O)NCc2cc(F)cc(F)c2)CC1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 4/20 0.43
EPHX2 P34913 1/20 0.43
THRB P10828 2/20 0.43
HPGD P15428 1/20 0.43
OPRM1 P35372 1/20 0.40
OPRL1 P41146 1/20 0.40
MAPT P10636 3/20 0.39
ALOX12 P18054 1/20 0.39
TP53 P04637 2/20 0.39
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.38
NPC1 O15118 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
P2RX7 Q99572 1/20 0.38
ALDH1A1 P00352 1/20 0.38
SSTR1 P30872 1/20 0.37
SSTR4 P31391 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL205370 0.93 SIGMAR1 (0.50) SIGMAR1EPHX2THRBHPGDOPRM1
SCHEMBL206772 0.93 EPHX2 (0.47) SIGMAR1EPHX2THRBHPGDMAPT
SCHEMBL207136 0.93 SMYD3 (0.42) SIGMAR1EPHX2THRBHPGDLMNA
SCHEMBL206617 0.90 SIGMAR1 (0.43) SIGMAR1EPHX2THRBHPGDOPRM1
SCHEMBL206406 0.90 EPHX1 (0.42) SIGMAR1HPGDLMNAPOLBNPC1
SCHEMBL206620 0.90 EPHX2 (0.46) SIGMAR1EPHX2THRBHPGDMAPT
SCHEMBL208251 0.89 SIGMAR1 (0.42) SIGMAR1EPHX2THRBHPGDOPRM1
SCHEMBL207581 0.88 POLB (0.46) SIGMAR1EPHX2THRBHPGDMAPT
SCHEMBL205944 0.88 LMNA (0.46) SIGMAR1EPHX2THRBHPGDOPRM1
SCHEMBL206160 0.88 ALDH1A1 (0.49) SIGMAR1EPHX2THRBHPGDOPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US claimed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP claimed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US claimed
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US disclosed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP disclosed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds PKD1, DDC, DPYD SIGMAR1 3262/4885EPHX2 1203/4885THRB 4068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.